Lawsuit says Bristol-Myers avoided $6.4 bln payment by delaying cancer drug_老虎社区_美港股上老虎

Lawsuit says Bristol-Myers avoided $6.4 bln payment by delaying cancer drug

Reuters2021-06-03

NEW YORK, June 3 (Reuters) - A new lawsuit claims Bristol-Myers Squibb Co improperly delayed the development of a drug to treat non-Hodgkin's lymphoma to avoid paying $6.4 billion to shareholders of the former Celgene Corp, which the drugmaker bought in 2019.

According to a complaint filed on Thursday in federal court in Manhattan, Bristol-Myers would have owed the money had it won U.S. Food and Drug Administration approval by specified deadlines for three drugs that Celgene had been developing.

The lawsuit said Bristol-Myers failed to use contractually required "diligent efforts" to win approval of the cancer drug Breyanzi by the Dec. 31, 2020, deadline, excusing it from the payments.

Bristol-Myers had no immediate comment.

The lawsuit was brought by UMB Bank NA, acting as a trustee for former Celgene shareholders it said lost out on the payments. Bristol-Myers bought Celgene in November 2019, and has valued the transaction at $80.3 billion.

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

CTLT
·2021-06-03
Why so many big companies get lawsuit?
回复
1
举报
OO_898
·2021-06-03
Omg
回复
1
举报
JY_02222
·2021-06-03
Wow
回复
1
举报
shaunlai
·2021-06-03
Cool
回复
2
举报
WWX2020
·2021-06-03
Test
回复
2
举报
收起
- RC_ADRIC:
  NIce
  2021-06-04
  回复
  举报
WWX2020
·2021-06-03
Wow cool
回复
3
举报
收起
- RC_ADRIC:
  Like and comment
  2021-06-04
  回复
  举报
Natdns
·2021-06-03
Like
回复
点赞
举报
CaptainMiya
·2021-06-03
[Salute] [Salute] [Salute] [Salute] [Salute]
回复
2
举报
收起
- Musztirom:
  👍
  2021-06-03
  回复
  举报
Deonc
·2021-06-03
Ok
回复
1
举报
收起
- WaiKeat6789:
  Ok
  2021-06-03
  回复
  举报
- WaiKeat6789:
  [Cool]
  2021-06-03
  回复
  举报
CaptainMiya
·2021-06-03
[Salute] [Salute] [Salute] [Salute] [Salute]
回复
1
举报
tralala
·2021-06-03
[Miser]
回复
点赞
举报
收起
- Ultraviolet:
  Like and comment
  2021-06-03
  回复
  举报
- RC_ADRIC:
  Like and comment
  2021-06-04
  回复
  举报
Khoogl
·2021-06-03
Like
回复
点赞
举报
收起
- JY_02222:
  Cool
  2021-06-03
  回复
  举报

热议股票

7x24

全部

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/2140424790?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-06-03 21:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2140424790","market":"us","top_or_hot":-1,"title":"Lawsuit says Bristol-Myers avoided $6.4 bln payment by delaying cancer drug","media":"Reuters","content":"<p>NEW YORK, June 3 (Reuters) - A new lawsuit claims Bristol-Myers Squibb Co improperly delayed the development of a drug to treat non-Hodgkin's lymphoma to avoid paying $6.4 billion to shareholders of the former Celgene Corp, which the drugmaker bought in 2019.</p>\n<p>According to a complaint filed on Thursday in federal court in <a href=\"https://laohu8.com/S/MHC.AU\">Manhattan</a>, Bristol-Myers would have owed the money had it won U.S. Food and Drug Administration approval by specified deadlines for three drugs that Celgene had been developing.</p>\n<p>The lawsuit said Bristol-Myers failed to use contractually required \"diligent efforts\" to win approval of the cancer drug Breyanzi by the Dec. 31, 2020, deadline, excusing it from the payments.</p>\n<p>Bristol-Myers had no immediate comment.</p>\n<p>The lawsuit was brought by UMB Bank NA, acting as a trustee for former Celgene shareholders it said lost out on the payments. Bristol-Myers bought Celgene in November 2019, and has valued the transaction at $80.3 billion.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lawsuit says Bristol-Myers avoided $6.4 bln payment by delaying cancer drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLawsuit says Bristol-Myers avoided $6.4 bln payment by delaying cancer drug\n</h2>\n\n<h4 class=\"meta\">\n\n2021-06-03 21:47 北京时间&nbsp;&nbsp;&nbsp;<strong>Reuters</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>NEW YORK, June 3 (Reuters) - A new lawsuit claims Bristol-Myers Squibb Co improperly delayed the development of a drug to treat non-Hodgkin's lymphoma to avoid paying $6.4 billion to shareholders of ...</p>\n\n<a href=\"None\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":null,"article_id":"2140424790","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2140424790","pubTimestamp":1622728058,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"NEW YORK, June 3 (Reuters) - A new lawsuit claims Bristol-Myers Squibb Co improperly delayed the dev","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"一项诉讼称，布里斯托尔-迈尔斯公司通过推迟癌症药物的使用而避免了64亿美元的赔付","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BMY":0.9},"content_text":"NEW YORK, June 3 (Reuters) - A new lawsuit claims Bristol-Myers Squibb Co improperly delayed the development of a drug to treat non-Hodgkin's lymphoma to avoid paying $6.4 billion to shareholders of the former Celgene Corp, which the drugmaker bought in 2019.\nAccording to a complaint filed on Thursday in federal court in Manhattan, Bristol-Myers would have owed the money had it won U.S. Food and Drug Administration approval by specified deadlines for three drugs that Celgene had been developing.\nThe lawsuit said Bristol-Myers failed to use contractually required \"diligent efforts\" to win approval of the cancer drug Breyanzi by the Dec. 31, 2020, deadline, excusing it from the payments.\nBristol-Myers had no immediate comment.\nThe lawsuit was brought by UMB Bank NA, acting as a trustee for former Celgene shareholders it said lost out on the payments. Bristol-Myers bought Celgene in November 2019, and has valued the transaction at $80.3 billion.","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":118282504,"gmtCreate":1622733661108,"gmtModify":1634098565257,"author":{"id":"3575034880210493","authorId":"3575034880210493","name":"CTLT","avatar":"https://static.tigerbbs.com/7281d38ef945e595e240f73b0b57e538","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3575034880210493","idStr":"3575034880210493"},"htmlText":"Why so many big companies get lawsuit?","listText":"Why so many big companies get lawsuit?","text":"Why so many big companies get lawsuit?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/118282504","repostId":2140424790,"repostType":4,"repost":{"id":"2140424790","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1622728058,"share":"https://www.laohu8.com/m/news/2140424790?lang=&edition=full","pubTime":"2021-06-03 21:47","market":"us","language":"en","title":"Lawsuit says Bristol-Myers avoided $6.4 bln payment by delaying cancer drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2140424790","media":"Reuters","summary":"NEW YORK, June 3 (Reuters) - A new lawsuit claims Bristol-Myers Squibb Co improperly delayed the dev","content":"<p>NEW YORK, June 3 (Reuters) - A new lawsuit claims Bristol-Myers Squibb Co improperly delayed the development of a drug to treat non-Hodgkin's lymphoma to avoid paying $6.4 billion to shareholders of the former Celgene Corp, which the drugmaker bought in 2019.</p>\n<p>According to a complaint filed on Thursday in federal court in <a href=\"https://laohu8.com/S/MHC.AU\">Manhattan</a>, Bristol-Myers would have owed the money had it won U.S. Food and Drug Administration approval by specified deadlines for three drugs that Celgene had been developing.</p>\n<p>The lawsuit said Bristol-Myers failed to use contractually required \"diligent efforts\" to win approval of the cancer drug Breyanzi by the Dec. 31, 2020, deadline, excusing it from the payments.</p>\n<p>Bristol-Myers had no immediate comment.</p>\n<p>The lawsuit was brought by UMB Bank NA, acting as a trustee for former Celgene shareholders it said lost out on the payments. Bristol-Myers bought Celgene in November 2019, and has valued the transaction at $80.3 billion.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lawsuit says Bristol-Myers avoided $6.4 bln payment by delaying cancer drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLawsuit says Bristol-Myers avoided $6.4 bln payment by delaying cancer drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-06-03 21:47</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>NEW YORK, June 3 (Reuters) - A new lawsuit claims Bristol-Myers Squibb Co improperly delayed the development of a drug to treat non-Hodgkin's lymphoma to avoid paying $6.4 billion to shareholders of the former Celgene Corp, which the drugmaker bought in 2019.</p>\n<p>According to a complaint filed on Thursday in federal court in <a href=\"https://laohu8.com/S/MHC.AU\">Manhattan</a>, Bristol-Myers would have owed the money had it won U.S. Food and Drug Administration approval by specified deadlines for three drugs that Celgene had been developing.</p>\n<p>The lawsuit said Bristol-Myers failed to use contractually required \"diligent efforts\" to win approval of the cancer drug Breyanzi by the Dec. 31, 2020, deadline, excusing it from the payments.</p>\n<p>Bristol-Myers had no immediate comment.</p>\n<p>The lawsuit was brought by UMB Bank NA, acting as a trustee for former Celgene shareholders it said lost out on the payments. Bristol-Myers bought Celgene in November 2019, and has valued the transaction at $80.3 billion.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BMY":"施贵宝"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2140424790","content_text":"NEW YORK, June 3 (Reuters) - A new lawsuit claims Bristol-Myers Squibb Co improperly delayed the development of a drug to treat non-Hodgkin's lymphoma to avoid paying $6.4 billion to shareholders of the former Celgene Corp, which the drugmaker bought in 2019.\nAccording to a complaint filed on Thursday in federal court in Manhattan, Bristol-Myers would have owed the money had it won U.S. Food and Drug Administration approval by specified deadlines for three drugs that Celgene had been developing.\nThe lawsuit said Bristol-Myers failed to use contractually required \"diligent efforts\" to win approval of the cancer drug Breyanzi by the Dec. 31, 2020, deadline, excusing it from the payments.\nBristol-Myers had no immediate comment.\nThe lawsuit was brought by UMB Bank NA, acting as a trustee for former Celgene shareholders it said lost out on the payments. Bristol-Myers bought Celgene in November 2019, and has valued the transaction at $80.3 billion.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":118290093,"gmtCreate":1622732509612,"gmtModify":1634098589739,"author":{"id":"3582969710070724","authorId":"3582969710070724","name":"OO_898","avatar":"https://static.tigerbbs.com/9fb3c360d5d7711641a868a144192fc7","vip":1,"crmLevel":4,"crmLevelSwitch":0,"authorIdStr":"3582969710070724","idStr":"3582969710070724"},"htmlText":"Omg","listText":"Omg","text":"Omg","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/118290093","repostId":2140424790,"repostType":4,"repost":{"id":"2140424790","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1622728058,"share":"https://www.laohu8.com/m/news/2140424790?lang=&edition=full","pubTime":"2021-06-03 21:47","market":"us","language":"en","title":"Lawsuit says Bristol-Myers avoided $6.4 bln payment by delaying cancer drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2140424790","media":"Reuters","summary":"NEW YORK, June 3 (Reuters) - A new lawsuit claims Bristol-Myers Squibb Co improperly delayed the dev","content":"<p>NEW YORK, June 3 (Reuters) - A new lawsuit claims Bristol-Myers Squibb Co improperly delayed the development of a drug to treat non-Hodgkin's lymphoma to avoid paying $6.4 billion to shareholders of the former Celgene Corp, which the drugmaker bought in 2019.</p>\n<p>According to a complaint filed on Thursday in federal court in <a href=\"https://laohu8.com/S/MHC.AU\">Manhattan</a>, Bristol-Myers would have owed the money had it won U.S. Food and Drug Administration approval by specified deadlines for three drugs that Celgene had been developing.</p>\n<p>The lawsuit said Bristol-Myers failed to use contractually required \"diligent efforts\" to win approval of the cancer drug Breyanzi by the Dec. 31, 2020, deadline, excusing it from the payments.</p>\n<p>Bristol-Myers had no immediate comment.</p>\n<p>The lawsuit was brought by UMB Bank NA, acting as a trustee for former Celgene shareholders it said lost out on the payments. Bristol-Myers bought Celgene in November 2019, and has valued the transaction at $80.3 billion.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lawsuit says Bristol-Myers avoided $6.4 bln payment by delaying cancer drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLawsuit says Bristol-Myers avoided $6.4 bln payment by delaying cancer drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-06-03 21:47</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>NEW YORK, June 3 (Reuters) - A new lawsuit claims Bristol-Myers Squibb Co improperly delayed the development of a drug to treat non-Hodgkin's lymphoma to avoid paying $6.4 billion to shareholders of the former Celgene Corp, which the drugmaker bought in 2019.</p>\n<p>According to a complaint filed on Thursday in federal court in <a href=\"https://laohu8.com/S/MHC.AU\">Manhattan</a>, Bristol-Myers would have owed the money had it won U.S. Food and Drug Administration approval by specified deadlines for three drugs that Celgene had been developing.</p>\n<p>The lawsuit said Bristol-Myers failed to use contractually required \"diligent efforts\" to win approval of the cancer drug Breyanzi by the Dec. 31, 2020, deadline, excusing it from the payments.</p>\n<p>Bristol-Myers had no immediate comment.</p>\n<p>The lawsuit was brought by UMB Bank NA, acting as a trustee for former Celgene shareholders it said lost out on the payments. Bristol-Myers bought Celgene in November 2019, and has valued the transaction at $80.3 billion.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BMY":"施贵宝"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2140424790","content_text":"NEW YORK, June 3 (Reuters) - A new lawsuit claims Bristol-Myers Squibb Co improperly delayed the development of a drug to treat non-Hodgkin's lymphoma to avoid paying $6.4 billion to shareholders of the former Celgene Corp, which the drugmaker bought in 2019.\nAccording to a complaint filed on Thursday in federal court in Manhattan, Bristol-Myers would have owed the money had it won U.S. Food and Drug Administration approval by specified deadlines for three drugs that Celgene had been developing.\nThe lawsuit said Bristol-Myers failed to use contractually required \"diligent efforts\" to win approval of the cancer drug Breyanzi by the Dec. 31, 2020, deadline, excusing it from the payments.\nBristol-Myers had no immediate comment.\nThe lawsuit was brought by UMB Bank NA, acting as a trustee for former Celgene shareholders it said lost out on the payments. Bristol-Myers bought Celgene in November 2019, and has valued the transaction at $80.3 billion.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":118606708,"gmtCreate":1622729383104,"gmtModify":1634098652074,"author":{"id":"3581989267840978","authorId":"3581989267840978","name":"JY_02222","avatar":"https://static.tigerbbs.com/56c9cab1743301942105239814a6ac4a","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3581989267840978","idStr":"3581989267840978"},"htmlText":"Wow&nbsp;","listText":"Wow&nbsp;","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/118606708","repostId":2140424790,"repostType":4,"repost":{"id":"2140424790","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1622728058,"share":"https://www.laohu8.com/m/news/2140424790?lang=&edition=full","pubTime":"2021-06-03 21:47","market":"us","language":"en","title":"Lawsuit says Bristol-Myers avoided $6.4 bln payment by delaying cancer drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2140424790","media":"Reuters","summary":"NEW YORK, June 3 (Reuters) - A new lawsuit claims Bristol-Myers Squibb Co improperly delayed the dev","content":"<p>NEW YORK, June 3 (Reuters) - A new lawsuit claims Bristol-Myers Squibb Co improperly delayed the development of a drug to treat non-Hodgkin's lymphoma to avoid paying $6.4 billion to shareholders of the former Celgene Corp, which the drugmaker bought in 2019.</p>\n<p>According to a complaint filed on Thursday in federal court in <a href=\"https://laohu8.com/S/MHC.AU\">Manhattan</a>, Bristol-Myers would have owed the money had it won U.S. Food and Drug Administration approval by specified deadlines for three drugs that Celgene had been developing.</p>\n<p>The lawsuit said Bristol-Myers failed to use contractually required \"diligent efforts\" to win approval of the cancer drug Breyanzi by the Dec. 31, 2020, deadline, excusing it from the payments.</p>\n<p>Bristol-Myers had no immediate comment.</p>\n<p>The lawsuit was brought by UMB Bank NA, acting as a trustee for former Celgene shareholders it said lost out on the payments. Bristol-Myers bought Celgene in November 2019, and has valued the transaction at $80.3 billion.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lawsuit says Bristol-Myers avoided $6.4 bln payment by delaying cancer drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLawsuit says Bristol-Myers avoided $6.4 bln payment by delaying cancer drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-06-03 21:47</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>NEW YORK, June 3 (Reuters) - A new lawsuit claims Bristol-Myers Squibb Co improperly delayed the development of a drug to treat non-Hodgkin's lymphoma to avoid paying $6.4 billion to shareholders of the former Celgene Corp, which the drugmaker bought in 2019.</p>\n<p>According to a complaint filed on Thursday in federal court in <a href=\"https://laohu8.com/S/MHC.AU\">Manhattan</a>, Bristol-Myers would have owed the money had it won U.S. Food and Drug Administration approval by specified deadlines for three drugs that Celgene had been developing.</p>\n<p>The lawsuit said Bristol-Myers failed to use contractually required \"diligent efforts\" to win approval of the cancer drug Breyanzi by the Dec. 31, 2020, deadline, excusing it from the payments.</p>\n<p>Bristol-Myers had no immediate comment.</p>\n<p>The lawsuit was brought by UMB Bank NA, acting as a trustee for former Celgene shareholders it said lost out on the payments. Bristol-Myers bought Celgene in November 2019, and has valued the transaction at $80.3 billion.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BMY":"施贵宝"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2140424790","content_text":"NEW YORK, June 3 (Reuters) - A new lawsuit claims Bristol-Myers Squibb Co improperly delayed the development of a drug to treat non-Hodgkin's lymphoma to avoid paying $6.4 billion to shareholders of the former Celgene Corp, which the drugmaker bought in 2019.\nAccording to a complaint filed on Thursday in federal court in Manhattan, Bristol-Myers would have owed the money had it won U.S. Food and Drug Administration approval by specified deadlines for three drugs that Celgene had been developing.\nThe lawsuit said Bristol-Myers failed to use contractually required \"diligent efforts\" to win approval of the cancer drug Breyanzi by the Dec. 31, 2020, deadline, excusing it from the payments.\nBristol-Myers had no immediate comment.\nThe lawsuit was brought by UMB Bank NA, acting as a trustee for former Celgene shareholders it said lost out on the payments. Bristol-Myers bought Celgene in November 2019, and has valued the transaction at $80.3 billion.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":118600748,"gmtCreate":1622729227184,"gmtModify":1634098654919,"author":{"id":"3576796739177144","authorId":"3576796739177144","name":"shaunlai","avatar":"https://static.tigerbbs.com/2d731c4b02ba125fc67096c7ed33ff55","vip":1,"crmLevel":3,"crmLevelSwitch":0,"authorIdStr":"3576796739177144","idStr":"3576796739177144"},"htmlText":"Cool&nbsp;","listText":"Cool&nbsp;","text":"Cool","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/118600748","repostId":2140424790,"repostType":4,"repost":{"id":"2140424790","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1622728058,"share":"https://www.laohu8.com/m/news/2140424790?lang=&edition=full","pubTime":"2021-06-03 21:47","market":"us","language":"en","title":"Lawsuit says Bristol-Myers avoided $6.4 bln payment by delaying cancer drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2140424790","media":"Reuters","summary":"NEW YORK, June 3 (Reuters) - A new lawsuit claims Bristol-Myers Squibb Co improperly delayed the dev","content":"<p>NEW YORK, June 3 (Reuters) - A new lawsuit claims Bristol-Myers Squibb Co improperly delayed the development of a drug to treat non-Hodgkin's lymphoma to avoid paying $6.4 billion to shareholders of the former Celgene Corp, which the drugmaker bought in 2019.</p>\n<p>According to a complaint filed on Thursday in federal court in <a href=\"https://laohu8.com/S/MHC.AU\">Manhattan</a>, Bristol-Myers would have owed the money had it won U.S. Food and Drug Administration approval by specified deadlines for three drugs that Celgene had been developing.</p>\n<p>The lawsuit said Bristol-Myers failed to use contractually required \"diligent efforts\" to win approval of the cancer drug Breyanzi by the Dec. 31, 2020, deadline, excusing it from the payments.</p>\n<p>Bristol-Myers had no immediate comment.</p>\n<p>The lawsuit was brought by UMB Bank NA, acting as a trustee for former Celgene shareholders it said lost out on the payments. Bristol-Myers bought Celgene in November 2019, and has valued the transaction at $80.3 billion.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lawsuit says Bristol-Myers avoided $6.4 bln payment by delaying cancer drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLawsuit says Bristol-Myers avoided $6.4 bln payment by delaying cancer drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-06-03 21:47</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>NEW YORK, June 3 (Reuters) - A new lawsuit claims Bristol-Myers Squibb Co improperly delayed the development of a drug to treat non-Hodgkin's lymphoma to avoid paying $6.4 billion to shareholders of the former Celgene Corp, which the drugmaker bought in 2019.</p>\n<p>According to a complaint filed on Thursday in federal court in <a href=\"https://laohu8.com/S/MHC.AU\">Manhattan</a>, Bristol-Myers would have owed the money had it won U.S. Food and Drug Administration approval by specified deadlines for three drugs that Celgene had been developing.</p>\n<p>The lawsuit said Bristol-Myers failed to use contractually required \"diligent efforts\" to win approval of the cancer drug Breyanzi by the Dec. 31, 2020, deadline, excusing it from the payments.</p>\n<p>Bristol-Myers had no immediate comment.</p>\n<p>The lawsuit was brought by UMB Bank NA, acting as a trustee for former Celgene shareholders it said lost out on the payments. Bristol-Myers bought Celgene in November 2019, and has valued the transaction at $80.3 billion.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BMY":"施贵宝"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2140424790","content_text":"NEW YORK, June 3 (Reuters) - A new lawsuit claims Bristol-Myers Squibb Co improperly delayed the development of a drug to treat non-Hodgkin's lymphoma to avoid paying $6.4 billion to shareholders of the former Celgene Corp, which the drugmaker bought in 2019.\nAccording to a complaint filed on Thursday in federal court in Manhattan, Bristol-Myers would have owed the money had it won U.S. Food and Drug Administration approval by specified deadlines for three drugs that Celgene had been developing.\nThe lawsuit said Bristol-Myers failed to use contractually required \"diligent efforts\" to win approval of the cancer drug Breyanzi by the Dec. 31, 2020, deadline, excusing it from the payments.\nBristol-Myers had no immediate comment.\nThe lawsuit was brought by UMB Bank NA, acting as a trustee for former Celgene shareholders it said lost out on the payments. Bristol-Myers bought Celgene in November 2019, and has valued the transaction at $80.3 billion.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":118875292,"gmtCreate":1622729140816,"gmtModify":1634098657294,"author":{"id":"3581903272361795","authorId":"3581903272361795","name":"WWX2020","avatar":"https://static.tigerbbs.com/245714e5ed56129262fa83e84d303ea3","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3581903272361795","idStr":"3581903272361795"},"htmlText":"Test","listText":"Test","text":"Test","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/118875292","repostId":2140424790,"repostType":4,"repost":{"id":"2140424790","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1622728058,"share":"https://www.laohu8.com/m/news/2140424790?lang=&edition=full","pubTime":"2021-06-03 21:47","market":"us","language":"en","title":"Lawsuit says Bristol-Myers avoided $6.4 bln payment by delaying cancer drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2140424790","media":"Reuters","summary":"NEW YORK, June 3 (Reuters) - A new lawsuit claims Bristol-Myers Squibb Co improperly delayed the dev","content":"<p>NEW YORK, June 3 (Reuters) - A new lawsuit claims Bristol-Myers Squibb Co improperly delayed the development of a drug to treat non-Hodgkin's lymphoma to avoid paying $6.4 billion to shareholders of the former Celgene Corp, which the drugmaker bought in 2019.</p>\n<p>According to a complaint filed on Thursday in federal court in <a href=\"https://laohu8.com/S/MHC.AU\">Manhattan</a>, Bristol-Myers would have owed the money had it won U.S. Food and Drug Administration approval by specified deadlines for three drugs that Celgene had been developing.</p>\n<p>The lawsuit said Bristol-Myers failed to use contractually required \"diligent efforts\" to win approval of the cancer drug Breyanzi by the Dec. 31, 2020, deadline, excusing it from the payments.</p>\n<p>Bristol-Myers had no immediate comment.</p>\n<p>The lawsuit was brought by UMB Bank NA, acting as a trustee for former Celgene shareholders it said lost out on the payments. Bristol-Myers bought Celgene in November 2019, and has valued the transaction at $80.3 billion.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lawsuit says Bristol-Myers avoided $6.4 bln payment by delaying cancer drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLawsuit says Bristol-Myers avoided $6.4 bln payment by delaying cancer drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-06-03 21:47</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>NEW YORK, June 3 (Reuters) - A new lawsuit claims Bristol-Myers Squibb Co improperly delayed the development of a drug to treat non-Hodgkin's lymphoma to avoid paying $6.4 billion to shareholders of the former Celgene Corp, which the drugmaker bought in 2019.</p>\n<p>According to a complaint filed on Thursday in federal court in <a href=\"https://laohu8.com/S/MHC.AU\">Manhattan</a>, Bristol-Myers would have owed the money had it won U.S. Food and Drug Administration approval by specified deadlines for three drugs that Celgene had been developing.</p>\n<p>The lawsuit said Bristol-Myers failed to use contractually required \"diligent efforts\" to win approval of the cancer drug Breyanzi by the Dec. 31, 2020, deadline, excusing it from the payments.</p>\n<p>Bristol-Myers had no immediate comment.</p>\n<p>The lawsuit was brought by UMB Bank NA, acting as a trustee for former Celgene shareholders it said lost out on the payments. Bristol-Myers bought Celgene in November 2019, and has valued the transaction at $80.3 billion.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BMY":"施贵宝"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2140424790","content_text":"NEW YORK, June 3 (Reuters) - A new lawsuit claims Bristol-Myers Squibb Co improperly delayed the development of a drug to treat non-Hodgkin's lymphoma to avoid paying $6.4 billion to shareholders of the former Celgene Corp, which the drugmaker bought in 2019.\nAccording to a complaint filed on Thursday in federal court in Manhattan, Bristol-Myers would have owed the money had it won U.S. Food and Drug Administration approval by specified deadlines for three drugs that Celgene had been developing.\nThe lawsuit said Bristol-Myers failed to use contractually required \"diligent efforts\" to win approval of the cancer drug Breyanzi by the Dec. 31, 2020, deadline, excusing it from the payments.\nBristol-Myers had no immediate comment.\nThe lawsuit was brought by UMB Bank NA, acting as a trustee for former Celgene shareholders it said lost out on the payments. Bristol-Myers bought Celgene in November 2019, and has valued the transaction at $80.3 billion.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4568883,"gmtCreate":1622760866979,"gmtModify":1635338155298,"authorId":3574743613224710,"author":{"id":3574743613224710,"idStr":"3574743613224710","authorId":3574743613224710,"name":"RC_ADRIC","avatar":"https://static.tigerbbs.com/ff53482947c23ec372fe52411816b015","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":118875292,"type":1,"supId":0,"prevId":0,"content":"NIce","text":"NIce","html":"NIce"}],"langContent":"EN"},{"id":118872838,"gmtCreate":1622729111524,"gmtModify":1634098657908,"author":{"id":"3581903272361795","authorId":"3581903272361795","name":"WWX2020","avatar":"https://static.tigerbbs.com/245714e5ed56129262fa83e84d303ea3","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3581903272361795","idStr":"3581903272361795"},"htmlText":"Wow cool","listText":"Wow cool","text":"Wow cool","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/118872838","repostId":2140424790,"repostType":4,"repost":{"id":"2140424790","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1622728058,"share":"https://www.laohu8.com/m/news/2140424790?lang=&edition=full","pubTime":"2021-06-03 21:47","market":"us","language":"en","title":"Lawsuit says Bristol-Myers avoided $6.4 bln payment by delaying cancer drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2140424790","media":"Reuters","summary":"NEW YORK, June 3 (Reuters) - A new lawsuit claims Bristol-Myers Squibb Co improperly delayed the dev","content":"<p>NEW YORK, June 3 (Reuters) - A new lawsuit claims Bristol-Myers Squibb Co improperly delayed the development of a drug to treat non-Hodgkin's lymphoma to avoid paying $6.4 billion to shareholders of the former Celgene Corp, which the drugmaker bought in 2019.</p>\n<p>According to a complaint filed on Thursday in federal court in <a href=\"https://laohu8.com/S/MHC.AU\">Manhattan</a>, Bristol-Myers would have owed the money had it won U.S. Food and Drug Administration approval by specified deadlines for three drugs that Celgene had been developing.</p>\n<p>The lawsuit said Bristol-Myers failed to use contractually required \"diligent efforts\" to win approval of the cancer drug Breyanzi by the Dec. 31, 2020, deadline, excusing it from the payments.</p>\n<p>Bristol-Myers had no immediate comment.</p>\n<p>The lawsuit was brought by UMB Bank NA, acting as a trustee for former Celgene shareholders it said lost out on the payments. Bristol-Myers bought Celgene in November 2019, and has valued the transaction at $80.3 billion.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lawsuit says Bristol-Myers avoided $6.4 bln payment by delaying cancer drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLawsuit says Bristol-Myers avoided $6.4 bln payment by delaying cancer drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-06-03 21:47</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>NEW YORK, June 3 (Reuters) - A new lawsuit claims Bristol-Myers Squibb Co improperly delayed the development of a drug to treat non-Hodgkin's lymphoma to avoid paying $6.4 billion to shareholders of the former Celgene Corp, which the drugmaker bought in 2019.</p>\n<p>According to a complaint filed on Thursday in federal court in <a href=\"https://laohu8.com/S/MHC.AU\">Manhattan</a>, Bristol-Myers would have owed the money had it won U.S. Food and Drug Administration approval by specified deadlines for three drugs that Celgene had been developing.</p>\n<p>The lawsuit said Bristol-Myers failed to use contractually required \"diligent efforts\" to win approval of the cancer drug Breyanzi by the Dec. 31, 2020, deadline, excusing it from the payments.</p>\n<p>Bristol-Myers had no immediate comment.</p>\n<p>The lawsuit was brought by UMB Bank NA, acting as a trustee for former Celgene shareholders it said lost out on the payments. Bristol-Myers bought Celgene in November 2019, and has valued the transaction at $80.3 billion.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BMY":"施贵宝"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2140424790","content_text":"NEW YORK, June 3 (Reuters) - A new lawsuit claims Bristol-Myers Squibb Co improperly delayed the development of a drug to treat non-Hodgkin's lymphoma to avoid paying $6.4 billion to shareholders of the former Celgene Corp, which the drugmaker bought in 2019.\nAccording to a complaint filed on Thursday in federal court in Manhattan, Bristol-Myers would have owed the money had it won U.S. Food and Drug Administration approval by specified deadlines for three drugs that Celgene had been developing.\nThe lawsuit said Bristol-Myers failed to use contractually required \"diligent efforts\" to win approval of the cancer drug Breyanzi by the Dec. 31, 2020, deadline, excusing it from the payments.\nBristol-Myers had no immediate comment.\nThe lawsuit was brought by UMB Bank NA, acting as a trustee for former Celgene shareholders it said lost out on the payments. Bristol-Myers bought Celgene in November 2019, and has valued the transaction at $80.3 billion.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4568885,"gmtCreate":1622760877591,"gmtModify":1635338155055,"authorId":3574743613224710,"author":{"id":3574743613224710,"idStr":"3574743613224710","authorId":3574743613224710,"name":"RC_ADRIC","avatar":"https://static.tigerbbs.com/ff53482947c23ec372fe52411816b015","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":118872838,"type":1,"supId":0,"prevId":0,"content":"Like and comment","text":"Like and comment","html":"Like and comment"}],"langContent":"EN"},{"id":118847971,"gmtCreate":1622728940593,"gmtModify":1634098662469,"author":{"id":"3576319038001885","authorId":"3576319038001885","name":"Natdns","avatar":"https://static.tigerbbs.com/be6cb184b10d5e613602b38d396409cf","vip":1,"crmLevel":4,"crmLevelSwitch":0,"authorIdStr":"3576319038001885","idStr":"3576319038001885"},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/118847971","repostId":2140424790,"repostType":4,"repost":{"id":"2140424790","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1622728058,"share":"https://www.laohu8.com/m/news/2140424790?lang=&edition=full","pubTime":"2021-06-03 21:47","market":"us","language":"en","title":"Lawsuit says Bristol-Myers avoided $6.4 bln payment by delaying cancer drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2140424790","media":"Reuters","summary":"NEW YORK, June 3 (Reuters) - A new lawsuit claims Bristol-Myers Squibb Co improperly delayed the dev","content":"<p>NEW YORK, June 3 (Reuters) - A new lawsuit claims Bristol-Myers Squibb Co improperly delayed the development of a drug to treat non-Hodgkin's lymphoma to avoid paying $6.4 billion to shareholders of the former Celgene Corp, which the drugmaker bought in 2019.</p>\n<p>According to a complaint filed on Thursday in federal court in <a href=\"https://laohu8.com/S/MHC.AU\">Manhattan</a>, Bristol-Myers would have owed the money had it won U.S. Food and Drug Administration approval by specified deadlines for three drugs that Celgene had been developing.</p>\n<p>The lawsuit said Bristol-Myers failed to use contractually required \"diligent efforts\" to win approval of the cancer drug Breyanzi by the Dec. 31, 2020, deadline, excusing it from the payments.</p>\n<p>Bristol-Myers had no immediate comment.</p>\n<p>The lawsuit was brought by UMB Bank NA, acting as a trustee for former Celgene shareholders it said lost out on the payments. Bristol-Myers bought Celgene in November 2019, and has valued the transaction at $80.3 billion.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lawsuit says Bristol-Myers avoided $6.4 bln payment by delaying cancer drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLawsuit says Bristol-Myers avoided $6.4 bln payment by delaying cancer drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-06-03 21:47</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>NEW YORK, June 3 (Reuters) - A new lawsuit claims Bristol-Myers Squibb Co improperly delayed the development of a drug to treat non-Hodgkin's lymphoma to avoid paying $6.4 billion to shareholders of the former Celgene Corp, which the drugmaker bought in 2019.</p>\n<p>According to a complaint filed on Thursday in federal court in <a href=\"https://laohu8.com/S/MHC.AU\">Manhattan</a>, Bristol-Myers would have owed the money had it won U.S. Food and Drug Administration approval by specified deadlines for three drugs that Celgene had been developing.</p>\n<p>The lawsuit said Bristol-Myers failed to use contractually required \"diligent efforts\" to win approval of the cancer drug Breyanzi by the Dec. 31, 2020, deadline, excusing it from the payments.</p>\n<p>Bristol-Myers had no immediate comment.</p>\n<p>The lawsuit was brought by UMB Bank NA, acting as a trustee for former Celgene shareholders it said lost out on the payments. Bristol-Myers bought Celgene in November 2019, and has valued the transaction at $80.3 billion.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BMY":"施贵宝"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2140424790","content_text":"NEW YORK, June 3 (Reuters) - A new lawsuit claims Bristol-Myers Squibb Co improperly delayed the development of a drug to treat non-Hodgkin's lymphoma to avoid paying $6.4 billion to shareholders of the former Celgene Corp, which the drugmaker bought in 2019.\nAccording to a complaint filed on Thursday in federal court in Manhattan, Bristol-Myers would have owed the money had it won U.S. Food and Drug Administration approval by specified deadlines for three drugs that Celgene had been developing.\nThe lawsuit said Bristol-Myers failed to use contractually required \"diligent efforts\" to win approval of the cancer drug Breyanzi by the Dec. 31, 2020, deadline, excusing it from the payments.\nBristol-Myers had no immediate comment.\nThe lawsuit was brought by UMB Bank NA, acting as a trustee for former Celgene shareholders it said lost out on the payments. Bristol-Myers bought Celgene in November 2019, and has valued the transaction at $80.3 billion.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":118822616,"gmtCreate":1622728388735,"gmtModify":1634098675270,"author":{"id":"3583738006388208","authorId":"3583738006388208","name":"CaptainMiya","avatar":"https://static.tigerbbs.com/48b66794427d9d57f06bb85d96e46757","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3583738006388208","idStr":"3583738006388208"},"htmlText":"[Salute]&nbsp;[Salute]&nbsp;[Salute]&nbsp;[Salute]&nbsp;[Salute]&nbsp;","listText":"[Salute]&nbsp;[Salute]&nbsp;[Salute]&nbsp;[Salute]&nbsp;[Salute]&nbsp;","text":"[Salute] [Salute] [Salute] [Salute] [Salute]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/118822616","repostId":2140424790,"repostType":4,"repost":{"id":"2140424790","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1622728058,"share":"https://www.laohu8.com/m/news/2140424790?lang=&edition=full","pubTime":"2021-06-03 21:47","market":"us","language":"en","title":"Lawsuit says Bristol-Myers avoided $6.4 bln payment by delaying cancer drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2140424790","media":"Reuters","summary":"NEW YORK, June 3 (Reuters) - A new lawsuit claims Bristol-Myers Squibb Co improperly delayed the dev","content":"<p>NEW YORK, June 3 (Reuters) - A new lawsuit claims Bristol-Myers Squibb Co improperly delayed the development of a drug to treat non-Hodgkin's lymphoma to avoid paying $6.4 billion to shareholders of the former Celgene Corp, which the drugmaker bought in 2019.</p>\n<p>According to a complaint filed on Thursday in federal court in <a href=\"https://laohu8.com/S/MHC.AU\">Manhattan</a>, Bristol-Myers would have owed the money had it won U.S. Food and Drug Administration approval by specified deadlines for three drugs that Celgene had been developing.</p>\n<p>The lawsuit said Bristol-Myers failed to use contractually required \"diligent efforts\" to win approval of the cancer drug Breyanzi by the Dec. 31, 2020, deadline, excusing it from the payments.</p>\n<p>Bristol-Myers had no immediate comment.</p>\n<p>The lawsuit was brought by UMB Bank NA, acting as a trustee for former Celgene shareholders it said lost out on the payments. Bristol-Myers bought Celgene in November 2019, and has valued the transaction at $80.3 billion.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lawsuit says Bristol-Myers avoided $6.4 bln payment by delaying cancer drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLawsuit says Bristol-Myers avoided $6.4 bln payment by delaying cancer drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-06-03 21:47</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>NEW YORK, June 3 (Reuters) - A new lawsuit claims Bristol-Myers Squibb Co improperly delayed the development of a drug to treat non-Hodgkin's lymphoma to avoid paying $6.4 billion to shareholders of the former Celgene Corp, which the drugmaker bought in 2019.</p>\n<p>According to a complaint filed on Thursday in federal court in <a href=\"https://laohu8.com/S/MHC.AU\">Manhattan</a>, Bristol-Myers would have owed the money had it won U.S. Food and Drug Administration approval by specified deadlines for three drugs that Celgene had been developing.</p>\n<p>The lawsuit said Bristol-Myers failed to use contractually required \"diligent efforts\" to win approval of the cancer drug Breyanzi by the Dec. 31, 2020, deadline, excusing it from the payments.</p>\n<p>Bristol-Myers had no immediate comment.</p>\n<p>The lawsuit was brought by UMB Bank NA, acting as a trustee for former Celgene shareholders it said lost out on the payments. Bristol-Myers bought Celgene in November 2019, and has valued the transaction at $80.3 billion.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BMY":"施贵宝"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2140424790","content_text":"NEW YORK, June 3 (Reuters) - A new lawsuit claims Bristol-Myers Squibb Co improperly delayed the development of a drug to treat non-Hodgkin's lymphoma to avoid paying $6.4 billion to shareholders of the former Celgene Corp, which the drugmaker bought in 2019.\nAccording to a complaint filed on Thursday in federal court in Manhattan, Bristol-Myers would have owed the money had it won U.S. Food and Drug Administration approval by specified deadlines for three drugs that Celgene had been developing.\nThe lawsuit said Bristol-Myers failed to use contractually required \"diligent efforts\" to win approval of the cancer drug Breyanzi by the Dec. 31, 2020, deadline, excusing it from the payments.\nBristol-Myers had no immediate comment.\nThe lawsuit was brought by UMB Bank NA, acting as a trustee for former Celgene shareholders it said lost out on the payments. Bristol-Myers bought Celgene in November 2019, and has valued the transaction at $80.3 billion.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4566332,"gmtCreate":1622734538252,"gmtModify":1635338345206,"authorId":3581560330669557,"author":{"id":3581560330669557,"idStr":"3581560330669557","authorId":3581560330669557,"name":"Musztirom","avatar":"https://community-static.tradeup.com/news/b5e59779a1eaa1b3dc28886ab0efa184","vip":2,"crmLevel":8,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":118822616,"type":1,"supId":0,"prevId":0,"content":"👍","text":"👍","html":"👍"}],"langContent":"EN"},{"id":118826781,"gmtCreate":1622728383443,"gmtModify":1634098675515,"author":{"id":"3569316529855154","authorId":"3569316529855154","name":"Deonc","avatar":"https://static.tigerbbs.com/d9aa45dd2eb58357f6477dcfb99d1415","vip":1,"crmLevel":3,"crmLevelSwitch":0,"authorIdStr":"3569316529855154","idStr":"3569316529855154"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/118826781","repostId":2140424790,"repostType":4,"repost":{"id":"2140424790","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1622728058,"share":"https://www.laohu8.com/m/news/2140424790?lang=&edition=full","pubTime":"2021-06-03 21:47","market":"us","language":"en","title":"Lawsuit says Bristol-Myers avoided $6.4 bln payment by delaying cancer drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2140424790","media":"Reuters","summary":"NEW YORK, June 3 (Reuters) - A new lawsuit claims Bristol-Myers Squibb Co improperly delayed the dev","content":"<p>NEW YORK, June 3 (Reuters) - A new lawsuit claims Bristol-Myers Squibb Co improperly delayed the development of a drug to treat non-Hodgkin's lymphoma to avoid paying $6.4 billion to shareholders of the former Celgene Corp, which the drugmaker bought in 2019.</p>\n<p>According to a complaint filed on Thursday in federal court in <a href=\"https://laohu8.com/S/MHC.AU\">Manhattan</a>, Bristol-Myers would have owed the money had it won U.S. Food and Drug Administration approval by specified deadlines for three drugs that Celgene had been developing.</p>\n<p>The lawsuit said Bristol-Myers failed to use contractually required \"diligent efforts\" to win approval of the cancer drug Breyanzi by the Dec. 31, 2020, deadline, excusing it from the payments.</p>\n<p>Bristol-Myers had no immediate comment.</p>\n<p>The lawsuit was brought by UMB Bank NA, acting as a trustee for former Celgene shareholders it said lost out on the payments. Bristol-Myers bought Celgene in November 2019, and has valued the transaction at $80.3 billion.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lawsuit says Bristol-Myers avoided $6.4 bln payment by delaying cancer drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLawsuit says Bristol-Myers avoided $6.4 bln payment by delaying cancer drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-06-03 21:47</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>NEW YORK, June 3 (Reuters) - A new lawsuit claims Bristol-Myers Squibb Co improperly delayed the development of a drug to treat non-Hodgkin's lymphoma to avoid paying $6.4 billion to shareholders of the former Celgene Corp, which the drugmaker bought in 2019.</p>\n<p>According to a complaint filed on Thursday in federal court in <a href=\"https://laohu8.com/S/MHC.AU\">Manhattan</a>, Bristol-Myers would have owed the money had it won U.S. Food and Drug Administration approval by specified deadlines for three drugs that Celgene had been developing.</p>\n<p>The lawsuit said Bristol-Myers failed to use contractually required \"diligent efforts\" to win approval of the cancer drug Breyanzi by the Dec. 31, 2020, deadline, excusing it from the payments.</p>\n<p>Bristol-Myers had no immediate comment.</p>\n<p>The lawsuit was brought by UMB Bank NA, acting as a trustee for former Celgene shareholders it said lost out on the payments. Bristol-Myers bought Celgene in November 2019, and has valued the transaction at $80.3 billion.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BMY":"施贵宝"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2140424790","content_text":"NEW YORK, June 3 (Reuters) - A new lawsuit claims Bristol-Myers Squibb Co improperly delayed the development of a drug to treat non-Hodgkin's lymphoma to avoid paying $6.4 billion to shareholders of the former Celgene Corp, which the drugmaker bought in 2019.\nAccording to a complaint filed on Thursday in federal court in Manhattan, Bristol-Myers would have owed the money had it won U.S. Food and Drug Administration approval by specified deadlines for three drugs that Celgene had been developing.\nThe lawsuit said Bristol-Myers failed to use contractually required \"diligent efforts\" to win approval of the cancer drug Breyanzi by the Dec. 31, 2020, deadline, excusing it from the payments.\nBristol-Myers had no immediate comment.\nThe lawsuit was brought by UMB Bank NA, acting as a trustee for former Celgene shareholders it said lost out on the payments. Bristol-Myers bought Celgene in November 2019, and has valued the transaction at $80.3 billion.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4564800,"gmtCreate":1622729340691,"gmtModify":1635338447072,"authorId":3578671423672074,"author":{"id":3578671423672074,"idStr":"3578671423672074","authorId":3578671423672074,"name":"WaiKeat6789","avatar":"https://static.tigerbbs.com/b06933547917cf61d68a480d7c087a86","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":118826781,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"},{"id":4565361,"gmtCreate":1622730879983,"gmtModify":1635338408709,"authorId":3578671423672074,"author":{"id":3578671423672074,"idStr":"3578671423672074","authorId":3578671423672074,"name":"WaiKeat6789","avatar":"https://static.tigerbbs.com/b06933547917cf61d68a480d7c087a86","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":118826781,"type":1,"supId":4564800,"prevId":0,"content":"[Cool]","text":"[Cool]","html":"[Cool]"}],"langContent":"EN"},{"id":118826081,"gmtCreate":1622728374943,"gmtModify":1634098675881,"author":{"id":"3583738006388208","authorId":"3583738006388208","name":"CaptainMiya","avatar":"https://static.tigerbbs.com/48b66794427d9d57f06bb85d96e46757","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3583738006388208","idStr":"3583738006388208"},"htmlText":"[Salute]&nbsp;[Salute]&nbsp;[Salute]&nbsp;[Salute]&nbsp;[Salute]&nbsp;","listText":"[Salute]&nbsp;[Salute]&nbsp;[Salute]&nbsp;[Salute]&nbsp;[Salute]&nbsp;","text":"[Salute] [Salute] [Salute] [Salute] [Salute]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/118826081","repostId":2140424790,"repostType":4,"repost":{"id":"2140424790","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1622728058,"share":"https://www.laohu8.com/m/news/2140424790?lang=&edition=full","pubTime":"2021-06-03 21:47","market":"us","language":"en","title":"Lawsuit says Bristol-Myers avoided $6.4 bln payment by delaying cancer drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2140424790","media":"Reuters","summary":"NEW YORK, June 3 (Reuters) - A new lawsuit claims Bristol-Myers Squibb Co improperly delayed the dev","content":"<p>NEW YORK, June 3 (Reuters) - A new lawsuit claims Bristol-Myers Squibb Co improperly delayed the development of a drug to treat non-Hodgkin's lymphoma to avoid paying $6.4 billion to shareholders of the former Celgene Corp, which the drugmaker bought in 2019.</p>\n<p>According to a complaint filed on Thursday in federal court in <a href=\"https://laohu8.com/S/MHC.AU\">Manhattan</a>, Bristol-Myers would have owed the money had it won U.S. Food and Drug Administration approval by specified deadlines for three drugs that Celgene had been developing.</p>\n<p>The lawsuit said Bristol-Myers failed to use contractually required \"diligent efforts\" to win approval of the cancer drug Breyanzi by the Dec. 31, 2020, deadline, excusing it from the payments.</p>\n<p>Bristol-Myers had no immediate comment.</p>\n<p>The lawsuit was brought by UMB Bank NA, acting as a trustee for former Celgene shareholders it said lost out on the payments. Bristol-Myers bought Celgene in November 2019, and has valued the transaction at $80.3 billion.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lawsuit says Bristol-Myers avoided $6.4 bln payment by delaying cancer drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLawsuit says Bristol-Myers avoided $6.4 bln payment by delaying cancer drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-06-03 21:47</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>NEW YORK, June 3 (Reuters) - A new lawsuit claims Bristol-Myers Squibb Co improperly delayed the development of a drug to treat non-Hodgkin's lymphoma to avoid paying $6.4 billion to shareholders of the former Celgene Corp, which the drugmaker bought in 2019.</p>\n<p>According to a complaint filed on Thursday in federal court in <a href=\"https://laohu8.com/S/MHC.AU\">Manhattan</a>, Bristol-Myers would have owed the money had it won U.S. Food and Drug Administration approval by specified deadlines for three drugs that Celgene had been developing.</p>\n<p>The lawsuit said Bristol-Myers failed to use contractually required \"diligent efforts\" to win approval of the cancer drug Breyanzi by the Dec. 31, 2020, deadline, excusing it from the payments.</p>\n<p>Bristol-Myers had no immediate comment.</p>\n<p>The lawsuit was brought by UMB Bank NA, acting as a trustee for former Celgene shareholders it said lost out on the payments. Bristol-Myers bought Celgene in November 2019, and has valued the transaction at $80.3 billion.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BMY":"施贵宝"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2140424790","content_text":"NEW YORK, June 3 (Reuters) - A new lawsuit claims Bristol-Myers Squibb Co improperly delayed the development of a drug to treat non-Hodgkin's lymphoma to avoid paying $6.4 billion to shareholders of the former Celgene Corp, which the drugmaker bought in 2019.\nAccording to a complaint filed on Thursday in federal court in Manhattan, Bristol-Myers would have owed the money had it won U.S. Food and Drug Administration approval by specified deadlines for three drugs that Celgene had been developing.\nThe lawsuit said Bristol-Myers failed to use contractually required \"diligent efforts\" to win approval of the cancer drug Breyanzi by the Dec. 31, 2020, deadline, excusing it from the payments.\nBristol-Myers had no immediate comment.\nThe lawsuit was brought by UMB Bank NA, acting as a trustee for former Celgene shareholders it said lost out on the payments. Bristol-Myers bought Celgene in November 2019, and has valued the transaction at $80.3 billion.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":118864865,"gmtCreate":1622728240357,"gmtModify":1634098678809,"author":{"id":"3573204828888286","authorId":"3573204828888286","name":"tralala","avatar":"https://static.tigerbbs.com/13cca168e92d8ddc7e3fb3e6f0291475","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3573204828888286","idStr":"3573204828888286"},"htmlText":"[Miser]&nbsp;","listText":"[Miser]&nbsp;","text":"[Miser]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/118864865","repostId":2140424790,"repostType":4,"repost":{"id":"2140424790","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1622728058,"share":"https://www.laohu8.com/m/news/2140424790?lang=&edition=full","pubTime":"2021-06-03 21:47","market":"us","language":"en","title":"Lawsuit says Bristol-Myers avoided $6.4 bln payment by delaying cancer drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2140424790","media":"Reuters","summary":"NEW YORK, June 3 (Reuters) - A new lawsuit claims Bristol-Myers Squibb Co improperly delayed the dev","content":"<p>NEW YORK, June 3 (Reuters) - A new lawsuit claims Bristol-Myers Squibb Co improperly delayed the development of a drug to treat non-Hodgkin's lymphoma to avoid paying $6.4 billion to shareholders of the former Celgene Corp, which the drugmaker bought in 2019.</p>\n<p>According to a complaint filed on Thursday in federal court in <a href=\"https://laohu8.com/S/MHC.AU\">Manhattan</a>, Bristol-Myers would have owed the money had it won U.S. Food and Drug Administration approval by specified deadlines for three drugs that Celgene had been developing.</p>\n<p>The lawsuit said Bristol-Myers failed to use contractually required \"diligent efforts\" to win approval of the cancer drug Breyanzi by the Dec. 31, 2020, deadline, excusing it from the payments.</p>\n<p>Bristol-Myers had no immediate comment.</p>\n<p>The lawsuit was brought by UMB Bank NA, acting as a trustee for former Celgene shareholders it said lost out on the payments. Bristol-Myers bought Celgene in November 2019, and has valued the transaction at $80.3 billion.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lawsuit says Bristol-Myers avoided $6.4 bln payment by delaying cancer drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLawsuit says Bristol-Myers avoided $6.4 bln payment by delaying cancer drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-06-03 21:47</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>NEW YORK, June 3 (Reuters) - A new lawsuit claims Bristol-Myers Squibb Co improperly delayed the development of a drug to treat non-Hodgkin's lymphoma to avoid paying $6.4 billion to shareholders of the former Celgene Corp, which the drugmaker bought in 2019.</p>\n<p>According to a complaint filed on Thursday in federal court in <a href=\"https://laohu8.com/S/MHC.AU\">Manhattan</a>, Bristol-Myers would have owed the money had it won U.S. Food and Drug Administration approval by specified deadlines for three drugs that Celgene had been developing.</p>\n<p>The lawsuit said Bristol-Myers failed to use contractually required \"diligent efforts\" to win approval of the cancer drug Breyanzi by the Dec. 31, 2020, deadline, excusing it from the payments.</p>\n<p>Bristol-Myers had no immediate comment.</p>\n<p>The lawsuit was brought by UMB Bank NA, acting as a trustee for former Celgene shareholders it said lost out on the payments. Bristol-Myers bought Celgene in November 2019, and has valued the transaction at $80.3 billion.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BMY":"施贵宝"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2140424790","content_text":"NEW YORK, June 3 (Reuters) - A new lawsuit claims Bristol-Myers Squibb Co improperly delayed the development of a drug to treat non-Hodgkin's lymphoma to avoid paying $6.4 billion to shareholders of the former Celgene Corp, which the drugmaker bought in 2019.\nAccording to a complaint filed on Thursday in federal court in Manhattan, Bristol-Myers would have owed the money had it won U.S. Food and Drug Administration approval by specified deadlines for three drugs that Celgene had been developing.\nThe lawsuit said Bristol-Myers failed to use contractually required \"diligent efforts\" to win approval of the cancer drug Breyanzi by the Dec. 31, 2020, deadline, excusing it from the payments.\nBristol-Myers had no immediate comment.\nThe lawsuit was brought by UMB Bank NA, acting as a trustee for former Celgene shareholders it said lost out on the payments. Bristol-Myers bought Celgene in November 2019, and has valued the transaction at $80.3 billion.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4564685,"gmtCreate":1622728934119,"gmtModify":1635338454514,"authorId":3580342534451795,"author":{"id":3580342534451795,"idStr":"3580342534451795","authorId":3580342534451795,"name":"Ultraviolet","avatar":"https://static.tigerbbs.com/0a37729d59392a2fd9ac9c4dbe50e826","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":118864865,"type":1,"supId":0,"prevId":0,"content":"Like and comment","text":"Like and comment","html":"Like and comment"},{"id":4568904,"gmtCreate":1622760978384,"gmtModify":1635338153462,"authorId":3574743613224710,"author":{"id":3574743613224710,"idStr":"3574743613224710","authorId":3574743613224710,"name":"RC_ADRIC","avatar":"https://static.tigerbbs.com/ff53482947c23ec372fe52411816b015","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":118864865,"type":1,"supId":4564685,"prevId":0,"content":"Like and comment","text":"Like and comment","html":"Like and comment"}],"langContent":"EN"},{"id":118863208,"gmtCreate":1622728137104,"gmtModify":1634098681478,"author":{"id":"3566032787349185","authorId":"3566032787349185","name":"Khoogl","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3566032787349185","idStr":"3566032787349185"},"htmlText":"Like&nbsp;","listText":"Like&nbsp;","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/118863208","repostId":2140424790,"repostType":4,"repost":{"id":"2140424790","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1622728058,"share":"https://www.laohu8.com/m/news/2140424790?lang=&edition=full","pubTime":"2021-06-03 21:47","market":"us","language":"en","title":"Lawsuit says Bristol-Myers avoided $6.4 bln payment by delaying cancer drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2140424790","media":"Reuters","summary":"NEW YORK, June 3 (Reuters) - A new lawsuit claims Bristol-Myers Squibb Co improperly delayed the dev","content":"<p>NEW YORK, June 3 (Reuters) - A new lawsuit claims Bristol-Myers Squibb Co improperly delayed the development of a drug to treat non-Hodgkin's lymphoma to avoid paying $6.4 billion to shareholders of the former Celgene Corp, which the drugmaker bought in 2019.</p>\n<p>According to a complaint filed on Thursday in federal court in <a href=\"https://laohu8.com/S/MHC.AU\">Manhattan</a>, Bristol-Myers would have owed the money had it won U.S. Food and Drug Administration approval by specified deadlines for three drugs that Celgene had been developing.</p>\n<p>The lawsuit said Bristol-Myers failed to use contractually required \"diligent efforts\" to win approval of the cancer drug Breyanzi by the Dec. 31, 2020, deadline, excusing it from the payments.</p>\n<p>Bristol-Myers had no immediate comment.</p>\n<p>The lawsuit was brought by UMB Bank NA, acting as a trustee for former Celgene shareholders it said lost out on the payments. Bristol-Myers bought Celgene in November 2019, and has valued the transaction at $80.3 billion.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lawsuit says Bristol-Myers avoided $6.4 bln payment by delaying cancer drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLawsuit says Bristol-Myers avoided $6.4 bln payment by delaying cancer drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-06-03 21:47</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>NEW YORK, June 3 (Reuters) - A new lawsuit claims Bristol-Myers Squibb Co improperly delayed the development of a drug to treat non-Hodgkin's lymphoma to avoid paying $6.4 billion to shareholders of the former Celgene Corp, which the drugmaker bought in 2019.</p>\n<p>According to a complaint filed on Thursday in federal court in <a href=\"https://laohu8.com/S/MHC.AU\">Manhattan</a>, Bristol-Myers would have owed the money had it won U.S. Food and Drug Administration approval by specified deadlines for three drugs that Celgene had been developing.</p>\n<p>The lawsuit said Bristol-Myers failed to use contractually required \"diligent efforts\" to win approval of the cancer drug Breyanzi by the Dec. 31, 2020, deadline, excusing it from the payments.</p>\n<p>Bristol-Myers had no immediate comment.</p>\n<p>The lawsuit was brought by UMB Bank NA, acting as a trustee for former Celgene shareholders it said lost out on the payments. Bristol-Myers bought Celgene in November 2019, and has valued the transaction at $80.3 billion.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BMY":"施贵宝"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2140424790","content_text":"NEW YORK, June 3 (Reuters) - A new lawsuit claims Bristol-Myers Squibb Co improperly delayed the development of a drug to treat non-Hodgkin's lymphoma to avoid paying $6.4 billion to shareholders of the former Celgene Corp, which the drugmaker bought in 2019.\nAccording to a complaint filed on Thursday in federal court in Manhattan, Bristol-Myers would have owed the money had it won U.S. Food and Drug Administration approval by specified deadlines for three drugs that Celgene had been developing.\nThe lawsuit said Bristol-Myers failed to use contractually required \"diligent efforts\" to win approval of the cancer drug Breyanzi by the Dec. 31, 2020, deadline, excusing it from the payments.\nBristol-Myers had no immediate comment.\nThe lawsuit was brought by UMB Bank NA, acting as a trustee for former Celgene shareholders it said lost out on the payments. Bristol-Myers bought Celgene in November 2019, and has valued the transaction at $80.3 billion.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4564852,"gmtCreate":1622729484199,"gmtModify":1635338442828,"authorId":3581989267840978,"author":{"id":3581989267840978,"idStr":"3581989267840978","authorId":3581989267840978,"name":"JY_02222","avatar":"https://static.tigerbbs.com/56c9cab1743301942105239814a6ac4a","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":118863208,"type":1,"supId":0,"prevId":0,"content":"Cool","text":"Cool","html":"Cool"}],"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":29,"commentSize":12,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}